CTC count predicts survival in mBC
As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).
Infliximab effective in treatment of plaque-type psoriasis
As reported in the British Journal of Dermatology, of patients with plaque-type psoriasis (n=660) treated with infliximab (5 mg/kg) at weeks 0, 2, and 6, then q 8 weeks through week 50, 56.8% achieved PASI 75, 71.6% of whom maintained the response through week 98. Of patients who achieved PASI 75 by week 14, 64.7% maintained the response through week 50. Of patients who did not achieve PASI 75 by week 50, 66.3% achieved PASI 75 by week 98.
Hospital readmission rate in patients discharged on parenteral antibiotics
As reported in Clinical Infectious Diseases, the hospital readmission rate for patients (n=782) discharged on parenteral antibiotics was 26%. The mean patient age was 58 years. The leading diagnoses were bacteremia, osteomyelitis, and pyelonephritis. The indications for readmission included non-infection related (30%), worsening symptoms (29%), and new infections (19%). The ORs for readmission factors were as follows: each decade increase in age, 1.09; aminoglycoside use, 2.33; resistant organism, 1.57; and number of hospital discharges in prior 12 months, 1.20.